Status:
Ready to upload
Record number:
1953
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
N/A: This systematic review covers a variety of neoplasms that have in common transmission in the setting of renal transplantation.
Time to detection:
Several examples are given: the earliest average onset was seen with choriocarcinoma (mean 1.4 months, median 1.0 month, range 1 day-3 months) and the longest was for renal cancer (mean 40.2 months, median 10.5 months, range 0.3 months-18.8 years); lung cancer median time to diagnosis 13 months, melanoma median time to diagnosis 10.5 months, lymphoma median time 4.0 months, sarcoma median time 19.0 months, glioblastoma median time 10 months.
Alerting signals, symptoms, evidence of occurrence:
N/A
Demonstration of imputability or root cause:
N/A: Inclusion of articles for review included filter and consensus for reasonable assurance of donor transmission, discussed in Methods section.
Imputability grade:
Not Assessable
Groups audience:
Keywords:
Suggest new keywords:
Review article
Deceased donor
Living donor
Kidney transplant
Lymphoma, type not specified
Melanoma
Lung cancer, type not specified
Sarcoma, other or type not specified
Astrocytoma/glioblastoma multiforme (WHO grade 4)
Choriocarcinoma
Malignancy
RCC
Reference attachment:
Suggest references:
Xiao D, Craig JC, Chapman JR, Dominguez-Gil B, Tong A, Wong G. Donor cancer transmission in kidney transplantation: a systematic review. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013;13(10):2645-52.
Note:
Please clone the record for the following malignancies: renal cell carcinoma, melanoma, lung cancer type not specified, sarcoma other or type not specified, astrocytoma/glioblastoma multiforme, choriocarcinoma.
Expert comments for publication:
This systematic review incorporates results of 104 donor transmitted cancers from 69 separate studies. The most commonly transmitted cancers were renal cancer, melanoma, lymphoma and lung cancer. Except in cases of glioblastoma multiforme, donor cancer was not suspected prior to transplant. The worst survival was seen with melanoma and lung cancer (<50% survival @ 2 yr after transplant) and the best survival was seen with renal cancer (>70% survival @ 24+ months). Transmitted sarcoma also resulted in poor survival.
The authors conclude that organs from donors with a history of melanoma or lung cancer should not be used, but the use of kidneys from donors with a history of small and incidental renal cell carcinoma should be considered (assuming removal of any lesions prior to transplant).